semaglutide for nafld Pharmacotherapy Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2 semaglutide and nafld Therapeutic Effects

From the payer perspective, the adjusted total cost per patient for the GLP-1RA group was higher than that for the insulin group by US$969, and from the healthcare sector perspective, the adjusted total cost per patient for the GLP-1RA group was lower than that for the insulin group by US$342

Contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as well as previous pancreatitis or severe GI disorders

But because those studies followed different groups of people over different periods of time, researchers eventually compared the medications head-to-head in a roughly 16-month clinical trial involving more than 750 adults with obesity

Retatrutide is not FDA approved and Eli Lilly has not publicly confirmed a submission date